A61P 25/22
Anxiolytics
A61P25/22 (Anxiolytics) appears on 7,707 US grants and 11,852 published applications in this corpus.
Search patents in A61P- Granted patents
- 7,707
- Published applications
- 11,852
- Assignees
- 2,500
- Inventors
- 16,485
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 2 | 0 |
| 1980 | 2 | 0 |
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 3 | 0 |
| 1989 | 3 | 0 |
| 1990 | 9 | 0 |
| 1991 | 2 | 0 |
| 1992 | 6 | 0 |
| 1993 | 9 | 0 |
| 1994 | 18 | 0 |
| 1995 | 22 | 0 |
| 1996 | 29 | 0 |
| 1997 | 48 | 0 |
| 1998 | 50 | 0 |
| 1999 | 75 | 0 |
| 2000 | 109 | 0 |
| 2001 | 166 | 43 |
| 2002 | 236 | 293 |
| 2003 | 224 | 504 |
| 2004 | 212 | 671 |
| 2005 | 236 | 586 |
| 2006 | 311 | 645 |
| 2007 | 299 | 708 |
| 2008 | 326 | 765 |
| 2009 | 349 | 825 |
| 2010 | 455 | 1008 |
| 2011 | 466 | 756 |
| 2012 | 529 | 726 |
| 2013 | 523 | 522 |
| 2014 | 518 | 440 |
| 2015 | 370 | 429 |
| 2016 | 320 | 377 |
| 2017 | 335 | 383 |
| 2018 | 267 | 330 |
| 2019 | 234 | 299 |
| 2020 | 176 | 297 |
| 2021 | 179 | 246 |
| 2022 | 144 | 221 |
| 2023 | 128 | 228 |
| 2024 | 139 | 216 |
| 2025 | 103 | 192 |
| 2026 | 69 | 142 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin6 Oct 2026US 12,751,960 B2Compass Pathfinder Limited
- EAAT2 activators and methods of using thereof29 Sep 2026US 12,747,227 B2Ohio State Innovation Foundation
- Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors25 Aug 2026US 12,715,875 B2Dart NeuroScience, LLC
- Quinazoline-4(3H)-one derivatives as negative allosteric modulators of metabotropic glutamate receptor 225 Aug 2026US 12,715,879 B2Vanderbilt University
- Use of pridopidine for treating anxiety and depression18 Aug 2026US 12,708,619 B2Prilenia Neurotherapeutics Ltd.
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Microbiome-based GABA Cream with Chondroitin Sulfate Transdermal Delivery System8 Oct 2026US 2026/0306531 A1
- Oxysterols and methods of use thereof8 Oct 2026US 2026/0308197 A1Sage Therapeutics, Inc.
- Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders8 Oct 2026US 2026/0308198 A1Sage Therapeutics, Inc.
- Anxiolytic therapy8 Oct 2026US 2026/0308253 A1
Most cited
By later US patents
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005
- Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions616US 6,569,463 B2Lipocine Inc. · 2003
- Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents342US 6,309,663 B1Lipocine Inc. · 2001
- Pharmaceutical compositions containing an omega-3 fatty acid oil306US 6,284,268 B1Cyclosporine Therapeutics Limited · 2001